← Leaderboards
Akash Patnaik
University Of Chicago
$2,630,502
Attributed
$2,630,502
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,630,502 · 1
By mechanism
R01$2,630,502 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Derek Alan Wainwright$7,505,477
- Thomas F Gajewski$23,743,716
- Stefani Spranger$2,780,537
- Peter Aidan Savage$14,017,592
- Ezra Cohen$7,350,375
Others in their field
Other Rising Stars on “Immunotherapeutic Agent”
- Dhiraj Kumar Singh · Texas Biomedical Research Institute$3,900,756
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$3,854,926
- Courtney Cohen · Albert Einstein College Of Medicine$3,541,248
- Steven Bradfute · Albert Einstein College Of Medicine$3,407,726
- Jimmy D Gollihar · Albert Einstein College Of Medicine$3,140,777
- Eytan Stein · Sloan-Kettering Inst Can Research$3,114,721
Research focus
Immunotherapeutic AgentImmuneGenetically Engineered MouseImmune Checkpoint InhibitorAntibodiesBypassCancer CellAgonistCancer PatientAntitumor ResponseCellsClinical ResearchClinical TrialsCombinatorialCombined Modality TherapyCyclic GmpAnti-CancerDna DamageDna Double Strand BreakExtracellular VesiclesFoundationsGene ActivationGenerationsInfiltration
Grant awards (4)
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer$1,063,904
R01 · FY2025 · CA · contact PI
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer$507,942
R01 · FY2024 · CA · contact PI
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer$523,982
R01 · FY2023 · CA · contact PI
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer$534,674
R01 · FY2022 · CA · contact PI